Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novo Nordisk A/S Announces Results from Tresiba Study


Monday, 24 Jun 2013 01:59am EDT 

Novo Nordisk A/S announced that it presented a study showing that Tresiba patients have a better health-related quality of life compared to patients on insulin Lantus from Sanofi French. There is a better physical health, partly because Tresiba-patients receive fewer cases of low blood sugar, but also because patients had statistically significant benefits in relation to exercise capacity, such as the ability to go and get dressed, and experienced less physical pain. The data comes from a one-year extension study, which together with the original study gives data from two years of trials. The overall results are based on 659 patients who completed the extension study, including 505 Tresiba patients and 154 Lantus patients.